William Blair reiterated their buy rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a report published on Tuesday, AnalystRatings.com reports.

A number of other brokerages have also weighed in on ASMB. Zacks Investment Research lowered shares of ExlService from a hold rating to a sell rating in a report on Wednesday, July 10th. BidaskClub lowered shares of Walgreens Boots Alliance from a sell rating to a strong sell rating in a report on Monday, June 24th. Finally, Chardan Capital reiterated a hold rating on shares of Assembly Biosciences in a report on Sunday, June 30th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $41.20.

Shares of ASMB opened at $13.00 on Tuesday. The company has a fifty day moving average of $14.11. Assembly Biosciences has a fifty-two week low of $12.75 and a fifty-two week high of $44.65. The company has a current ratio of 7.97, a quick ratio of 7.97 and a debt-to-equity ratio of 0.06.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.06) by $0.01. The company had revenue of $3.89 million for the quarter, compared to analyst estimates of $3.81 million. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. Sell-side analysts forecast that Assembly Biosciences will post -4.34 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of ASMB. RTW Investments LP acquired a new position in shares of Assembly Biosciences during the 4th quarter valued at $15,532,000. FMR LLC lifted its holdings in shares of Assembly Biosciences by 136.0% during the 4th quarter. FMR LLC now owns 443,036 shares of the biopharmaceutical company’s stock valued at $10,021,000 after acquiring an additional 255,336 shares in the last quarter. Emerald Advisers LLC lifted its holdings in shares of Assembly Biosciences by 20.3% during the 1st quarter. Emerald Advisers LLC now owns 468,379 shares of the biopharmaceutical company’s stock valued at $9,222,000 after acquiring an additional 79,039 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Assembly Biosciences by 3.4% during the 4th quarter. BlackRock Inc. now owns 1,909,510 shares of the biopharmaceutical company’s stock valued at $43,193,000 after acquiring an additional 63,554 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust lifted its holdings in shares of Assembly Biosciences by 13.3% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 418,143 shares of the biopharmaceutical company’s stock valued at $8,233,000 after acquiring an additional 49,230 shares in the last quarter. Institutional investors and hedge funds own 86.44% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Story: How do CD ladders protect against rising interest rates?

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.